1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Malignant Mesothelioma Global Clinical Trials Review, H2, 2016

Malignant Mesothelioma Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Malignant Mesothelioma Global Clinical Trials Review, H2, 2016" provides an overview of Malignant Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Mesothelioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Malignant Mesothelioma Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Malignant Mesothelioma Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Malignant Mesothelioma 29
Nov 17, 2016: Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma 29
Oct 31, 2016: Selecta Biosciences Collaborators at the National Cancer Institute Present Preclinical Data Showing SVP-Rapamycin Application to Cancer Therapy 29
Oct 21, 2016: Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy 30
Clinical Trial Profile Snapshots 31
Appendix 285
Abbreviations 285
Definitions 285
Research Methodology 286
Secondary Research 286
About GlobalData 287
Contact Us 287
Disclaimer 287
Source 288

List of Tables
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region, 2016* 6
Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 286

Companies Mentioned
Eli Lilly and Company
AstraZeneca Plc
Merck and Co Inc
Novartis AG
F. Hoffmann-La Roche Ltd
Pfizer Inc
Bayer AG
Sellas Inc
Eisai Co Ltd
Bristol-Myers Squibb Company

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Lung Cancer Surgery Market by Procedure, Minimally Invasive, Device, Monitoring, Endoscopic Instrument - Global Forecast to 2021

Lung Cancer Surgery Market by Procedure, Minimally Invasive, Device, Monitoring, Endoscopic Instrument - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The lung cancer surgery market is projected to reach USD 29.99 billion by 2021 from USD 21.58 billion in 2016, at a CAGR of 6.8% from 2016 to 2021. The global lung cancer surgery market is segmented based ...

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics ...


Download Unlimited Documents from Trusted Public Sources

Lymphoma Statistics in Germany

  • March 2017
    167 pages
  • Lymphoma  

    Cancer  

    Leukemia  

  • Germany  

    Europe  

    United States  

View report >

Hospital Statistics in the US

  • March 2017
    16 pages
  • Hospital  

    Breast Cancer  

  • United States  

View report >

Colorectal Cancer Statistics in Norway and the US

  • March 2017
    6 pages
  • Colorectal Canc...  

    Cancer  

    Therapy  

  • United States  

    Norway  

View report >

Related Market Segments :

Lung Cancer
Cancer
Therapy
Chemotherapy
Cell Therapy

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.